

Pfizer Completes Acquisition Of InnoPharma

Thursday, September 25, 2014 - 04:00am

Pfizer Inc. (NYSE:PFE) today announced that it has completed its acquisition of the pharmaceutical development company, InnoPharma, Inc., following receipt of United States (U.S.) regulatory approval from all government authorities required by the agreement and other closing conditions.

“We believe this acquisition will help Pfizer build a strong sterile injectables pipeline in areas such as oncology and central nervous disorders,” said John Young, group president, Pfizer Global Established Pharma (GEP). “Sterile injectables is one of several areas of potential growth for GEP. This acquisition reflects our continued view that attractive growth opportunities, both external and organic, exist for the business.”

Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com.

PFIZER DISCLOSURE NOTICE

The information contained in this release is as of September 25, 2014. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about Pfizer's acquisition of InnoPharma that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to

approve any applications for InnoPharma's product candidates, as well as their decisions regarding labeling and other matters that could affect their availability or commercial potential; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and in its subsequent reports on Form 10-Q and Form 8-K.

Media: Joan Campion, 212-733-2798 Mobile: 201-761-9384 Joan.Campion@pfizer.com or Investor: Ryan Crowe, 212-733-8160 Mobile: 215-260-0914 Ryan.Crowe@pfizer.com